Refresher Course: Physics in Medical Imaging

RC 213 - Considerations on radiation doses and associated risks in case of oncological patients' pathways: frequency and type of examinations in focus

February 26, 10:00 - 11:00 CET

5 min
Chairperson's introduction
Mika Kortesniemi, Espoo / Finland
15 min
Appropriate imaging in oncology
Denis Joseph J D'Almada Remedios, Harrow / United Kingdom
  1. To learn about the generic justification of imaging modalities used for diagnosis staging, planning and follow-up.
  2. To understand how the examination frequency might be adjusted for specific clinical situations for individual justification.
  3. To be aware of the role of radiology in managing patients with special innovative therapies, e.g. immunotherapy.
15 min
Recurrent medical imaging procedures in case of oncological patient's pathways
Agnieszka Kuchcinska, Warsaw / Poland
  1. To evaluate which malignancies could be associated with the highest level of radiation doses due to medical imaging.
  2. To learn about possible cumulative effective dose levels in the case of patients taking part in successful clinical trials: a case study: adult patients with melanoma.
  3. To understand how to use cumulative effective dose concept in optimising planned exposure series during treatment and follow-up: a paediatric patient with an osteosarcoma case study.
15 min
Radiation protection issues concerns: cumulative doses and possible radiation risk
Marco Brambilla, Novara / Italy
  1. To understand the possible risk associated with single medical low-dose exposure and risk associated with a series of recurrent exposures.
  2. To learn about the possibilities of dose tracking systems that help manage patients' cumulative radiation doses.
  3. To learn about global discussion and current consensus on the possible approach to optimisation and management of planned medical exposure series.
10 min
Panel discussion: How to choose the appropriate medical imaging modality and frequency of examinations in case of patients receiving innovative oncological therapy?